Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...

The final trades of the day with the Fast Money traders.

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Johnson & Johnson (NYSE:JNJ – Get Free Report) was the target of some unusual options trading on Thursday. Stock traders purchased 58,414 call options on the stock. This is an increase of ...

Johnson & Johnson (JNJ) begins on Tuesday its third attempt to push through a multi-billion-dollar settlement relating to ...

Sanctuary Advisors LLC cut its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 10.4% during the fourth quarter, ...

Johnson & Johnson faces a critical test on Tuesday over its $10 billion proposal to end litigation alleging that its baby ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

Key Insights Significantly high institutional ownership implies Johnson & Johnson's stock price is sensitive to ...

Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a ...

Pharmaceutical giant Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for $1 billion ...

The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates of $22.4 billion and $2.02, respectively.